DEN240064 is an FDA 510(k) submission (not cleared) for the CT-132. Classified as Computerized Behavioral Therapy Device For Migraine (product code SEE), Class II - Special Controls.
Submitted by Click Therapeutics, Inc. (New York, US). The FDA issued a Not Cleared (DENG) decision on April 11, 2025 after a review of 150 days.
This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.5806 - the FDA neurology device framework. The Traditional 510(k) pathway requires demonstration of substantial equivalence to a legally marketed predicate device - a standard the FDA determined was not met in this submission.
Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. This submission did not achieve clearance, indicating the FDA determined the device lacked sufficient predicate equivalence under the Neurology review framework.